 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...56789101112131415...1920» |
- || sofosbuvir/velpatasvir / Generic mfg.
84 días ininterrumpidos para detener la #hepatitisc y mejorar mi estado de salud #tratamientohepatitis #hepatitis #epclusa @GileadSciences @CdmxClinica @SSaludCdMx @SSalud_mx (Twitter) - Sep 5, 2021
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir (clinicaltrials.gov) - Sep 5, 2021
P1, N=10, Recruiting, Sponsor: Catherine Chappell
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
- || ribavirin / Generic mfg.
Clinical, Journal: Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus co-infected patients in Myanmar. (Pubmed Central) - Sep 2, 2021
Participants co-infected with HBV were treated concurrently with tenofovir...However, the estimated average cost of the intervention (under the assumption of no genotype testing and reduced real-world effectiveness) of $1250/patient is unaffordable for a national elimination strategy. Reductions in the cost of antivirals and linkage to social and behavioral health services including substance use disorder treatment to increase retention and adherence to treament are critical to HCV elimination in this population.
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis. (Pubmed Central) - Sep 2, 2021
This analysis informs payers that SOF/VEL should continue to be reimbursed in decompensated hepatitis C patients. It also supports the recommendations by the American Association for the Study of Liver Diseases to continue screening for HCC in decompensated cirrhotic patients who have achieved sustained virologic response.
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Je suis têtue. Investir dans des #traitements. Beaucoup de virus comme l’hépatite C [ HARVONI®, SOVALDI®, EPCLUSA®, VOSEVI®, MAVIRET® et ZEPATIER®...] et même le virus du sida sont traités par des médicaments : https://t.co/R6p0INA3xV (Twitter) - Aug 26, 2021
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date: Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil (clinicaltrials.gov) - Aug 25, 2021
P=N/A, N=144, Active, not recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
It also supports the recommendations by the American Association for the Study of Liver Diseases to continue screening for HCC in decompensated cirrhotic patients who have achieved sustained virologic response. Trial completion date: Jun 2021 --> Nov 2021
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) (clinicaltrials.gov) - Aug 22, 2021
P4, N=1800, Not yet recruiting, Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd
- ribavirin / Generic mfg.
[VIRTUAL] Management of DAA Failures in Asia () - Aug 19, 2021 - Abstract #APDW2021APDW_385;
Trial completion date: Jun 2021 --> Nov 2021 The Taiwan HCV Registry (TACR) programme recently reported that the factors associated with DAA failure was DAA adherence 90% of patients with prior DAA failures can be successfully re-treated with sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir or glecaprevir/pibrentasvir if genotype, fibrosis, treatment history and RAS are taken into consideration.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, Real-world evidence: Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. (Pubmed Central) - Aug 18, 2021
Sofosbuvir-based therapy, including pangenotypic sofosbuvir/velpatasvir, is effective for the treatment of HCV in real-world clinical practice. This is an important step towards HCV elimination.
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. (Pubmed Central) - Aug 18, 2021
P4
DAA treatment scale-up was associated with reduced HCV incidence in prison, indicative of a beneficial effect of HCV treatment-as-prevention in this setting. These findings support broad DAA treatment scale-up within incarcerated populations.
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Review, Journal: Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. (Pubmed Central) - Aug 14, 2021
Although rare, the failure to the latest-generation regimens (grazoprevir/elbasvir, sofosbuvir/velpatasvir, pibrentasvir/glecaprevir) represents a serious clinical problem, since the data available in the literature on the virological characteristics and management of these patients are few. The aim of the present narrative review was to provide an overview of the impact of baseline RASs in patients treated with the latest-generation DAAs and to analyze the efficacy of the available retreatment strategies in those who have failed these regimens.
- || ribavirin / Generic mfg.
Clinical, Review, Journal: Meeting the WHO Hepatitis C Virus Elimination Goal: Review of Treatment in Pediatrics. (Pubmed Central) - Aug 12, 2021
Further studies are warranted to determine the optimal treatment for children with HCV infection, including timing, regimen, and duration. Additionally, with the recent pediatric approvals, long-term safety data is needed.
- || ribavirin / Generic mfg.
Clinical, Journal, Real-world evidence: A real-world study of sofosbuvir-based drug treatment for hepatitis C virus genotype 6 infection in Hainan region of China (Pubmed Central) - Aug 11, 2021
There were seven cases of adverse events, mainly including fatigue, anorexia, and mild anemia; however, no serious adverse events were reported. Sofosbuvir-based regimen combined with ribavirin or velpatasvir cannot only achieve high response rate to HCV subtype 6a, but also obtain a good sustained virological response to the rare prevalent sub-genotypes and special virus strains of HCV genotype 6, with mild adverse reactions and acceptable safety profile.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal: Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. (Pubmed Central) - Aug 11, 2021
None of the patients developed an SAE or required antiviral treatment withdrawal. SOF/VEL±RBV or GLE/PIB are safe and effective for treating G3-HCV-infections, with a lower effectiveness in patients with advanced fibrosis F3-4.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Clinical, Journal: Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. (Pubmed Central) - Aug 11, 2021
SOF/VEL/VOX is well tolerated and effective in treating patients who have been exposed to prior DAA therapy outside of clinical trials. SOF/VEL/VOX should be considered as the first-line regimen in HCV infected patients who have experienced prior DAA failure.
- || ribavirin / Generic mfg.
Clinical, Journal: Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. (Pubmed Central) - Aug 8, 2021
The multivariate logistic regression analysis recognized only the male gender and presence of ascites at baseline as the independent factors of non-response to treatment. It should be emphasized that despite the availability of pangenotypic, strong therapeutic options, GT3 infected patients with cirrhosis still remain difficult-to-treat, especially those with hepatic impairment and DAA-experienced.
- | Vemlidy (tenofovir alafenamide) / Gilead
New P4 trial: BDTAF: The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-na (clinicaltrials.gov) - Aug 8, 2021
P4, N=120, Recruiting, Sponsor: Peking University First Hospital
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Eight weeks of Sofosbuvir/Velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. (Pubmed Central) - Aug 8, 2021
This offers a non-protease inhibitor based 8-week regimen which may be useful for complex drug interactions or where time-limited opportunity for treatment. In limited resource settings, reduction in drug acquisition costs may help achieve progress towards the goal of HCV elimination.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Trial completion, Trial completion date, Trial primary completion date: USE-Hep C: Utilization of Hepatitis C Positive Kidneys in Negative Recipients (clinicaltrials.gov) - Aug 5, 2021
P2/3, N=30, Completed, Sponsor: Ohio State University
In limited resource settings, reduction in drug acquisition costs may help achieve progress towards the goal of HCV elimination. Recruiting --> Completed | Trial completion date: Jan 2022 --> Apr 2021 | Trial primary completion date: Jan 2021 --> Apr 2021
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, P4 data, Journal: Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C. (Pubmed Central) - Aug 5, 2021
P4
Results from KeY Treat will be presented at conferences and published in peer-reviewed journals. NCT03949764.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal: Utilization of Hepatitis C Viremic Donors for Liver Transplant Recipients without Hepatitis C. A Veterans Transplant Center Report. (Pubmed Central) - Aug 4, 2021
It shortened waiting time, allowing patients to receive transplants at lower MELD scores. VA liver transplant programs have provided universal and timely access to post-transplant HCV DAA therapy after donor-derived infection.
- || Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: Safety and Efficacy of Sofosbuvir and Velpatasvir In Children With Active Hepatitis C Virus Infection Undergoing Haploidentical Transplantation. (Pubmed Central) - Aug 4, 2021
With a median follow-up of 15 months, four patients are disease free with sustained VR. Our study shows that combination of Sof-Vel might be effective in inducing rapid complete and sustained VR during HCT without any major untoward drug interaction.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Observational data, Journal, Real-world evidence: Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. (Pubmed Central) - Aug 4, 2021
SOF/VEL was prescribed in patients with older age and with more cardiovascular and CNS comorbidities. Despite this, a proportion of contraindicated drugs lower than that of GLE/PIB was registered.
- sofosbuvir/velpatasvir / Generic mfg.
IT IS POSSIBLE TO ELIMINATE HCV IN HOMELESS PATIENTS: REAL-LIFE GROUP ANALYSIS OF HOMELESS PATIENTS WITH HCV TREATED WITH SOFOSBUVIR / VELPATASVIR (SOF / VEL) DURING 12 WEEKS () - Jul 31, 2021 - Abstract #AEEH2021AEEH_210;
- sofosbuvir/velpatasvir / Generic mfg.
EFFECTIVENESS OF SOFOSBUVIR / VELPATASVIR (SOF / VEL) IN PATIENTS WITH CHRONIC HCV INFECTION AND PSYCHIATRIC DISORDERS: RESULTS IN REAL CLINICAL PRACTICE IN 6 COUNTRIES () - Jul 31, 2021 - Abstract #AEEH2021AEEH_209;
- ||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: HCV Seek, Test and Rapid Treatment for Young PWID (clinicaltrials.gov) - Jul 28, 2021
P4, N=39, Completed, Sponsor: Weill Medical College of Cornell University
Despite this, a proportion of contraindicated drugs lower than that of GLE/PIB was registered. Recruiting --> Completed | N=72 --> 39 | Trial completion date: Jul 2022 --> Jun 2021 | Trial primary completion date: Jul 2022 --> Jun 2021
- || hydroxychloroquine / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. (Pubmed Central) - Jul 22, 2021
Although treatment with SOF/VEL was safe, adding SOF/VEL to the standard of care did not improve the clinical status or reduce mortality in patients with moderate to severe COVID-19. However, larger randomized clinical trials including more parameters are needed for accurate estimation of the efficacy of SOF/VEL.
- | ribavirin / Generic mfg.
Trial completion: MINMON: Monitoring SOF/VEL in Treatment Na (clinicaltrials.gov) - Jul 16, 2021
P4, N=400, Completed, Sponsor: AIDS Clinical Trials Group
However, larger randomized clinical trials including more parameters are needed for accurate estimation of the efficacy of SOF/VEL. Active, not recruiting --> Completed
- | sofosbuvir/velpatasvir / Generic mfg.
Phase classification: People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (clinicaltrials.gov) - Jul 14, 2021
P4, N=450, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Phase classification: P=N/A --> P4
- || sofosbuvir/velpatasvir / Generic mfg.
💊هيئة الغذاء والدواء توافق على الدواء المسمى تجاريًا إبكلسا Epclusa كعلاج للأطفال بعمر الـ3 سنوات فمافوق الذين يعانون من مرض التهاب الكبدي الوبائي (ج C) الشركة المصنعة للدواء جيلياد @GileadSciences قضت على الالتهاب الكبدي الوبائي(ج)في البالغين كذلك https://t.co/gsY6I7uM7B (2) (Twitter) - Jul 8, 2021
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Clinical, Journal: Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. (Pubmed Central) - Jul 7, 2021
Similar to reports from phase 3 clinical trials, SVV proved highly effective as salvage therapy for patients who failed a previous DAA therapy. Those who failed SVV had at least 2 of the following factors: genotype 3, presence of cirrhosis, past liver transplantation, past exposure to sofosbuvir/velpatasvir and/or complex resistance profiles.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Transplantation of Liver from Hepatitis C-infected Donors to Hepatitis C RNA Negative Recipients: Histological and Virologic Outcome. (Pubmed Central) - Jul 7, 2021
Those who failed SVV had at least 2 of the following factors: genotype 3, presence of cirrhosis, past liver transplantation, past exposure to sofosbuvir/velpatasvir and/or complex resistance profiles. At 1-year protocol liver-biopsy, patients had inflammation consistent with viral hepatitis despite the successful eradication of HCV.
- |||||| New trial, Real-world evidence, Real-world: C-DIAMOND: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (clinicaltrials.gov) - Jul 6, 2021
P, N=300, Recruiting, Sponsor: Qing XIe
- || sofosbuvir/velpatasvir / Generic mfg.
Trial completion: HepNet acute HCV-V: Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir (clinicaltrials.gov) - Jul 6, 2021
P2, N=20, Completed, Sponsor: Hannover Medical School
At 1-year protocol liver-biopsy, patients had inflammation consistent with viral hepatitis despite the successful eradication of HCV. Active, not recruiting --> Completed
- || sofosbuvir/velpatasvir / Generic mfg.
Trial completion: Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis (clinicaltrials.gov) - Jul 6, 2021
P3, N=37, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal: High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55-85. (Pubmed Central) - Jul 4, 2021
The overall rate of active infection was lower than the rate observed in the 1935-1954 cohort. The high rate of inpatients unaware of HCV infections and the high number of deaths among subjects with an active HCV infection born from 1935 to 1954, suggest that, at least in southern Italy, targeted screening of this birth cohort may be required to reduce the number of undiagnosed cases and hidden infections.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Thin-layer chromatography/fluorescence detection approach for sensitive and selective determination of hepatitis C virus antiviral (velpatasvir): application to human plasma. (Pubmed Central) - Jul 2, 2021
The suggested method could selectively determine velpatasvir with high sensitivity in a synthetic tablet powder containing a co-formulated anti-HCV drug (sofosbuvir) without any interference from excipients or sofosbuvir. In addition, the method was successfully applied for determination of velpatasvir in spiked human plasma with adequate % recovery.
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Observational data, Retrospective data, Journal: Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. (Pubmed Central) - Jul 2, 2021
In addition, the method was successfully applied for determination of velpatasvir in spiked human plasma with adequate % recovery. The performance of DAAs in PWUD is excellent, if 2 conditions are met: (i) that the latest generation drugs are used and (ii) that the patients are managed within the SerDs.
- || ribavirin / Generic mfg.
Clinical, Journal, Real-world evidence: Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. (Pubmed Central) - Jul 1, 2021
No severe adverse event occurred. Real-world data show that sofosbuvir-based regimens are highly effective and safe for patients with HCV genotypes 3 and 6 infections.
- | sofosbuvir/velpatasvir / Generic mfg.
New trial, Real-world evidence, Real-world effectiveness, Real-world: SOF/VEL (clinicaltrials.gov) - Jul 1, 2021
P, N=150, Recruiting, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Acute hepatitis C infection with secondary liver injury successfully treated with sofosbuvir/velpatasvir combination. (Pubmed Central) - Jul 1, 2021
Real-world data show that sofosbuvir-based regimens are highly effective and safe for patients with HCV genotypes 3 and 6 infections. No abstract available
- || sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Clinical, Observational data, Journal: Comparing direct acting antivirals for hepatitis C using observational data - Why and how? (Pubmed Central) - Jul 1, 2021
This risk difference is evidence that SOF/LDV is not inferior to SOF/VEL for easy to treat patients with genotype 1 HCV. The approach is a template for comparing drugs when there are no data from comparative trials.
- |||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: THINKER-NEXT: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (clinicaltrials.gov) - Jun 30, 2021
P2, N=400, Recruiting, Sponsor: University of Pennsylvania
The approach is a template for comparing drugs when there are no data from comparative trials. Not yet recruiting --> Recruiting
- || beclabuvir (BMS-791325) / BMS
Clinical, Journal: Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. (Pubmed Central) - Jun 30, 2021
Direct sequence analysis detected no additional variants within either the NS5A or NS5B regions at the time of relapse. In conclusion, three patients with prior NS5A-P32del-associated DAA treatment failure received 24 weeks of SOF/VEL + RBV therapy, and two of the patients achieved SVR12.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal: Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir. (Pubmed Central) - Jun 30, 2021
Thereafter, her serum ammonia level rapidly improved, and HE did not recur. Interventional radiology such as BRTO following SOF/VEL therapy may be a useful option even in patients with decompensated HCV-associated cirrhosis accompanied by portal-systemic shunt.
- sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Concordance of SVR 4-12-24 timepoints in an era of reduced sustained virologic response (SVR) determination () - Jun 27, 2021 - Abstract #EASLILC2021EASL_ILC_1737;
This early time point to confirm HCV may be important when monitoring a vulnerable population at high risk to be lost to follow-up. These data support minimal monitoring of HCV treatment and follow-up, and the EASL guidance that testing for SVR can be omitted in certain patients without compromising the treatment paradigm.
- ribavirin / Generic mfg.
[VIRTUAL] Telemedicine improve HCV elimination among Italian people who use drugs: an innovative therapeutic model to increase the adherence to treatment into addiction care centers. () - Jun 27, 2021 - Abstract #EASLILC2021EASL_ILC_1640;
We obtained a high SVR12 (98, 6%), providing a complete hepatologic assessment within addiction care center, tailoring the drug administration and performing a remote hepato- logic stewardship. Our therapeutic model should improve the time to treat and the adherence to treatment in PWUDs.
- || Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal: Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. (Pubmed Central) - Jun 26, 2021
RASs in NS5A were more prevalent than in NS3 and were frequently observed as dual and triple combination patterns, with a high impact on NS5A inhibitor activity, particularly in genotypes 1a and 3a. Retreatment of glecaprevir/pibrentasvir failures with sofosbuvir/velpatasvir/voxilaprevir achieved viral suppression across all genotypes.
- | sofosbuvir/velpatasvir / Generic mfg.
Journal, HEOR: Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective. (Pubmed Central) - Jun 26, 2021
DAAs were cost-effective compared with traditional treatments. A reasonable reduction in the price of DAAs will increase drug affordability and is of great significance as a global strategy to eradicate viral hepatitis.
- || ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Clinical, Journal, HEOR, Real-world evidence: Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts. (Pubmed Central) - Jun 22, 2021
A reasonable reduction in the price of DAAs will increase drug affordability and is of great significance as a global strategy to eradicate viral hepatitis. In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis.